Illuminating the immune interface to develop new cancer therapies


The Enara Bio™ purpose
Shining a light on Dark Antigen™ and T-cell biology to enable people to live free from the shadow of cancer.
Enara Bio is exploring the hidden depths of cancer biology to discover and characterize novel immunotherapy targets, such as Dark Antigens derived from the genomic dark matter or cancer-specific antigens presented by MR1.
To achieve our mission, we have built a differentiated technology platform integrating bioinformatics, immunopeptidomics, metabolomics and immunology that enables us to interrogate both sides of the T-cell/cancer cell interface. Our growing team has the depth of expertise and breadth of experience to advance this exciting area of immuno-oncology for the benefit of broad groups of cancer patients and their families.
Read more about usOur team
We have established a core team of scientists, entrepreneurs and industry veterans to drive our research, development and clinical success.
View teamLatest News
-
Boehringer Ingelheim and Enara Bio enter Strategic Collaboration and Licensing Agreement to discover novel shared antigens for cancer immunotherapies Collaboration focuses on up to three types of lung and gastrointestinal (GI) cancers. Latest in a series of strategic acquisitions and partnerships that strengthens Boehringer Ingelheim’s position in the cancer vaccine and T-cell engager spaces. Agreement and partnership with Boehringer Ingelheim provides additional validation of Enara Bio’s EDAPT™ platform and Dark Antigen™ discovery work and supports ongoing cell therapy based therapeutic approach.
-
Enara Bio adds further world-class cell therapy and immuno-oncology expertise to Senior Management Team and Scientific Advisory Board Dr Erik Rutjens appointed as Vice President, Cell Therapy Operations Dr Sadik Kassim and Dr Michael Quigley strengthen Scientific Advisory Board with deep industry experience
-
Enara Bio relocates to The Oxford Science Park’s newest facility to expand R&D capabilities in the search for novel cancer immunotherapies Enara’s move from the Oxford BioEscalator to one of the UK's largest biomedical innovation centres is in preparation for its future growth and ambition to transform cancer care. The dedicated research facility will enable the company to accelerate the preclinical development of its lead MR1-targeting T-cell therapy program.